Completed PHASE1 INTERVENTIONAL 2-arm NCT02627287

A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions DV3316 pen-injector FlexPen® placebo

Updated 7 times since 2017 Last updated: Feb 6, 2018 Started: Dec 1, 2015 Primary completion: Feb 25, 2016 Completion: Feb 25, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Diabetes and Diabetes Mellitus, Type 1, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 7 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Mar 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mainz, Germany
• Neuss, Germany